A uterine malformation is a type of female genital malformation resulting from an abnormal development of the Müllerian duct(s) during embryogenesis. Symptoms range from amenorrhea, infertility, recurrent pregnancy loss, and pain, to normal functioning depending on the nature of the defect. Types
The American Fertility Society (now American Society of Reproductive Medicine) Classification distinguishes:

Class I—Müllerian agenesis (absent uterus). This condition is represented by the hypoplasia or the agenesis (total absence) of the different parts of the uterus:
Vaginal hypoplasia or agenesis
Cervical hypoplasia or agenesis
Fundal hypoplasia or agenesis (absence or hypoplasia of the fundus of the uterus)
Tubal hypoplasia or agenesis (absence or hypoplasia of the Fallopian tubes)
Combined hypoplasia the agenesis of different part of the uterus
This condition is also called Mayer-Rokitansky-Kuster-Hauser syndrome. The patient with MRKH syndrome will have primary amenorrhea. Class II—Unicornuate uterus (a one-sided uterus). Rare condition in which a partial or complete lack of one Müllerian duct is present. The uterus has a typical "banana shape" on imaging systems. This condition can be sub-classified in:
Communicating: a rudimentary uterine horn is formed and it presents a cavity that communicates with the body of the uterus
Non-communicating: a rudimentary uterine horn is formed and it presents a cavity that does not communicate with the body of the uterus
No cavity: a rudimentary uterine horn is present without any cavity
No horn: there is no rudimentary uterine horn, just the functioning one is presentClass III—Uterus didelphys, also uterus didelphis (double uterus). Both Müllerian ducts develop but fail to fuse, thus the patient has a "double uterus".
A third trial, Trial 3, was conducted during 2007–2008 in Gabon and Malawi.In Trial 1, the most common adverse reactions in participants with malaria treated with IV artesunate were acute renal failure requiring dialysis, hemoglobinuria and jaundice. The safety profile in Trial 2 was generally similar to Trial 1.One trial was used to evaluate both, safety and benefits of artesunate. The trial enrolled participants with severe malaria who needed hospitalization because of their condition. Participants received at random either artesunate or a medicine used to treat malaria (quinine). Participants and the health care providers knew which treatment was being given.The benefit of artesunate in comparison to quinine was evaluated by comparing the number of participants who died while in the hospital (in-hospital mortality).The benefit of artesunate was supported by the data from Trial 2 in which pediatric participants younger than 15 years of age with severe malaria were randomly assigned treatment with artesunate or quinine.The application for IV artesunate was granted priority review and orphan drug designations. The FDA granted approval of artesunate for injection to Amivas. References
External links

"Artesunate". Drug Information Portal. U.S. National Library of Medicine.